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Hepatitis C virus non-structural protein 3 contains a serine
protease and an RNA helicase. Protease cleaves the genome-
encoded polyprotein and inactivates cellular proteins required
for innate immunity. Protease has emerged as an important tar-
get for the development of antiviral therapeutics, but drug
resistance has turned out to be an obstacle in the clinic. Helicase
is required for both genome replication and virus assembly.
Mechanistic and structural studies of helicase have hurled this
enzyme into a prominent position in the field of helicase enzy-
mology. Nevertheless, studies of helicase as an antiviral target
remain in their infancy.
Hepatitis C virus (HCV)3 infection is a leading cause of
chronic liver disease and hepatocellular carcinoma. HCV is the
founding member of theHepacivirus genus of the family Flavi-
viridae (1). The HCV genome is a single-stranded RNA of pos-
itive polarity that is on the order of 9000 nucleotides (nt) in
length (Fig. 1a). The 5-non-translated region (NTR) contains a
terminal stem-loop that is a required cis-acting replication ele-
ment and the internal ribosome entry site. The 3-NTR con-
tains a cis-acting replication element that consists of an RNA
stem-loop of variable sequence, a polyuridine/polypyrimidine
tract of variable length, and a highly conserved “X-tail. ” The
variability observed in the 3-NTRand elsewhere in the genome
is sufficient to permit classification of HCV into six distinct
genotypes.
The HCV genome encodes a single open reading frame, the
translation of which is directed by the internal ribosome entry
site. The HCV polyprotein is on the order of 3000 amino acids
long and can be divided into a structural region (C–p7 proteins)
and a non-structural (NS) region (NS2–NS5B proteins) (Fig.
1a). Cleavage of the HCV polyprotein occurs co- and post-
translationally by host (structural region) and viral (non-struc-
tural region) proteases. Only the NS3–NS5B region of the
polyprotein is required for genome replication in cell culture
(2). NS5B is the viral RNA-dependent RNA polymerase (3).
NS5A is a phosphoprotein (4) capable of specifically interacting
with the 3-NTR of the HCV genome (5), other non-structural
proteins (6), and numerous cellular proteins (7, 8). NS5A also
functions in virus assembly (9, 10). NS4B is an integral mem-
brane protein that is required for assembly of the “membranous
web,” the organelle used for RNA replication (11, 12). NS4A is a
cofactor for NS3 that directs the localization of NS3 and mod-
ulates its enzymatic activities (13). TheN-terminal one-third of
NS3 contains the protease activity responsible for processing of
the non-structural region of the polyprotein (Fig. 1b) (14–16)
and some cellular proteins (17–19). The C-terminal two-thirds
of NS3 is an RNAhelicase of theDExH family (Fig. 1c) (20). The
biological function of the RNA helicase activity is not known
but may include 1) RNA folding/remodeling (21), 2) enhance-
ment of polymerase processivity (22), and/or 3) genome encap-
sidation (23).
The significance, if any, of having the major viral protease
tethered to the RNA helicase is not known. The protease
domain can function independently of the helicase domain and
vice versa. Evidence suggests that each domain modulates the
biochemical activity of the other (24, 25). Importantly, both the
protease domain andNS4Amodulate the RNAhelicase activity
of NS3 (26, 27). The ability to physically and functionally sepa-
rate the two activities of NS3 has fostered the development of
two diametrically opposed NS3 disciplines. Study of NS3 pro-
tease activity has been very practical, focusing on the pursuit of
inhibitors as specifically targeted antiviral therapy for hepatitis
C (STAT-C). Study of NS3 helicase activity has been much
more fundamental, focusing on the use of this helicase as a
model for the structure and mechanism of DExH proteins in
general. Here, we summarize our understanding of the struc-
ture, mechanism, and/or inhibition of both activities of NS3
and discuss the implications of the current state of the art on
future directions for studies of this very important yet incom-
pletely tapped antiviral target.
NS3 Protease
Structure, Substrate Recognition, and Catalytic Mechanism—
NS3 protease is a serine protease that belongs to the trypsin/
chymotrypsin protease superfamily (28, 29). The enzyme con-
sists of two -barrel domains that are flanked by two short
-helices (Fig. 1b). One of the -strands of the N-terminal
-barrel derives from the central hydrophobic region of NS4A.
The structure is stabilized by a Zn2 ion that is coordinated by
three cysteine residues and one water molecule (Fig. 1b). Zn2
binding is essential for function (30). The substrate-binding
pocket can accommodate six amino acid residues (P4–P2)
(Fig. 2a). However, cleavage efficiency is best when substrates
include 10 amino acid residues (P6–P4) (31), suggesting that
interactions of the substrate with the surface of NS3 occur.
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Protease activity requires a catalytic triad (Ser-139, His-57, and
Asp-81) and an oxyanion hole (backbone amides of Gly-137
and Ser-139) (Fig. 1b). The NS4A cofactor contributes to the
proper positioning of the catalytic triad and the substrate (32),
thus explaining its role in catalytic efficiency and substrate
specificity.
Similar to other viral proteases, NS3 protease substrates are
defined by multiple amino acid residues, not just those at the
scissile bond (P1–P1). The consensus cleavage site has cysteine
and serine at the scissile bond (Fig. 2a). Studies in vitro with
peptides have shown that cleavage at the NS5A/NS5B junction
is at least an order ofmagnitudemore efficient than observed at
other sites, including the NS4B/NS5A junction, which also has
cysteine and serine at the scissile bond (31). This observation is
consistent with the existence of multiple determinants of sub-
strate recognition. All of the studies that have evaluated the
substrate specificity of NS3 protease quantitatively have used
steady-state kinetics and parameters such as kcat, Km, and
kcat/Km to define this specificity.
The general assumption for serine
proteases is that kcat reports on for-
mation of the acyl-enzyme interme-
diatewith amides, i.e. release of both
product peptides is fast relative to
formation of this intermediate (33).
It is worth noting that seminal stud-
ies by De Francesco and co-workers
showed that some Pn-P1 product
peptides exhibit substantial inhibi-
tory activity that can be increased by
amino acid substitution (34). There-
fore, it is possible that the affinity of
theNS3 protease for theN-terminal
product peptide may alter the rate-
limiting step in the steady state.
Changes in rate-limiting steps such
as these have substantial contrain-
dications for the use of steady-state
kinetics alone to understand sub-
strate specificity of HCVNS3 prote-
ase. The addition of pre-steady-
state kinetic analysis to the study of
NS3 substrate specificity may be
warranted but has never been
reported.
The catalytic/chemical mecha-
nism of NS3 protease-catalyzed
cleavage of peptide bonds is likely
identical to that observed for other
serine proteases (33, 35) based on
the conservation of the catalytic
triad (Fig. 2b). His-57 is predicted to
serve as a general base to activate
the Ser-139 nucleophile. The pKa
value for His-57 is elevated to the
level required to deprotonate
Ser-139 by hydrogen bonding to
Asp-181, which likely also exhibits
an elevated pKa value. Once substrate binds, nucleophilic
attack of the carbonyl carbon of the scissile bond by Ser-139
leads to formation of a tetrahedral intermediate containing an
oxyanion (Fig. 2b) that is stabilized by the oxyanion hole of the
enzyme (Fig. 1b). Collapse of the tetrahedral intermediate pro-
duces an acyl-enzyme intermediate and the N-terminal prod-
uct peptide. Dissociation of this product peptide permits bind-
ing of water, hydrolysis of the acyl-enzyme intermediate, and
production of the C-terminal product peptide. Dissociation of
this product resets the system for another round of catalysis.
Antagonism of Innate Immunity—Pathogen-associated mo-
lecular patterns (PAMPs), such as pathogen-specific nucleic
acids, proteins, carbohydrates, and lipids, are recognized by
pathogen recognition receptors (PRRs). Toll-like receptors
(TLRs) are PRRs that are located on the cell surface and recog-
nize extracellular PAMPs, although some TLRs are capable of
detecting intracellular PAMPs. Most intracellular PAMPs are
detected by retinoic acid-inducible gene I (RIG-I)-like recep-
FIGURE 1. a, location of the NS3-coding sequence in the HCV genome. The cis-acting elements in the NTRs are
shown. The asterisk indicates the microRNA-122-binding site. Full-length NS3 protein is located from amino
acids 1027 to 1658 of the polyprotein of the genotype 1b consensus sequence (NCBI accession number
AJ238799) (2). IRES, internal ribosome entry site. b, structure of the NS3 protease domain in complex with the
NS4A cofactor and substrate peptide. The crystal structure (Protein Data Bank code 1A1R) of the N-terminal
protease domain (red) in complex with the NS4A peptide cofactor (purple) is rendered as a ribbon (28). The
polypeptide containing the NS3/NS4A junction, corresponding to positions P4 –P2, was modeled into
the active site of the NS3 protease and shown as surface (gray); the sequence of the peptide is shown next to
the structure. The polypeptide model, starting with its primary sequence, was constructed in-house. The
expanded views highlight the catalytic triad, the oxyanion hole, and the zinc-binding site. The lower left
expanded view displays the interactions of the catalytic triad (His-57, Asp-81, and Ser-139), rendered as ball-
and-stick, with the modeled peptide; black dashed lines represent the hydrogen bonds. The lower right
expanded view shows the oxyanion loop (positions 135–139), whose backbone nitrogen atoms play a role in
stabilizing the developing negative charge on the O of Ser-139 during the peptide cleavage; the side chains
are drawn as sticks, and the oxyanion hole is highlighted by the blue shadow. The top expanded view shows the
side chains of the key residues (Cys-97, Cys-99, Cys-145, and His-149), depicted as sticks, that interact with the
metal ion (purple sphere). c, structure of the NS3 helicase domain in complex with ssDNA and ADPAlF4
. Coor-
dinates are from Protein Data Bank code 3KQL (89). The conserved motifs of RNA helicases are colored and
indentified by established Roman numeral designations (62, 89). The expanded view shows the ATP transition
state analog in the NTP-binding/catalytic site of the enzyme.
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tors, including RIG-I and MDA5 (melanoma differentiation
antigen 5). Once engaged, PRRs activate the innate immune
response by inducing expression of interferon (IFN)-. Release
of IFN- then causes an auto- and paracrine response that
includes activation of IFN-stimulated genes, the products of
which are effectors of the innate immune response.
In the case of HCV infection, viral RNA is sensed by two
mechanisms. The first requires TLR3, which may detect viral
RNA during entry and uncoating of the virion. The second
requires RIG-I, which is thought to detect cytosolic HCV RNA
and its replication intermediates. PRRs recognize a variety of
features associated with HCV RNA, e.g. the 5-triphosphate
(36), double-stranded RNA associated with the NTRs (37), and
perhaps even single-stranded stretches like the polypyrimidine
tract (38).
Activation of TLR3 or RIG-I leads to activation (phosphory-
lation and dimerization) of IRF3 (interferon regulatory factor
3). Activated IRF3 translocates into the nucleus and transacti-
vates the IFN- promoter. The signaling pathway from PAMP-
activated TLR3 to activated IRF3 requires TRIF (Toll/interleu-
kin-1 receptor resistance domain-containing adaptor-inducing
IFNprotein) (39). The signaling pathway fromPAMP-activated
RIG-I to activated IRF3 requires MAVS (mitochondrial antivi-
ral signaling protein) (40). MAVS is also known as IFN- stim-
ulator protein 1 (41), virus-induced signaling adaptor (42), and
Cardif (43).
HCV infection is capable of blocking IRF3 activation in re-
sponse to PAMP engagement by TLR3 and RIG-I (17, 19, 44,
45). This antagonism of the innate immune response is medi-
ated by the NS3 protease activity
(17–19, 44, 45). Both TRIF and
MAVS are substrates forNS3 prote-
ase (17–19, 44, 45). As shown in Fig.
2a, both proteins are cleaved after a
cysteine residue as observed for
most NS3 protease substrates. Sim-
ilarities beyond the P1 position are
also apparent (Fig. 2a).
Inhibition, Inhibitor Resistance,
and the Substrate Envelope Hypoth-
esis—The significant experience of
the pharmaceutical industry in devel-
oping clinically useful inhibitors of
human immunodeficiency virus pro-
tease (HIVPR) led very early on to the
development of antiviral programs
targeting NS3 protease activity.
These early investments have filled
the pipeline with numerous com-
pounds that are at various stages
of clinical development. Although
NS3 protease andHIV PR have sim-
ilar roles in the viral life cycle
(polyprotein processing), NS3 pro-
tease also antagonizes activation
of the innate immune response.
Therefore, inhibition of NS3 prote-
ase activity will not only decrease
the efficiency of viral replication but will also restore, at least
partially, the innate immune response in HCV-infected cells.
Most NS3 protease inhibitors are competitive with the sub-
strate and thus target the substrate-binding site (Fig. 3a). The
earliest inhibitors were based on product peptides (46). Efforts
to remove reactive groups and create molecules with enhanced
pharmacological properties led to the development of macro-
cyclic compounds (Fig. 3b), and it was this class of compounds
that were used in the first proof-of-concept clinical studies (47).
Although these initial macrocyclic compounds were never
approved, newmacrocyclic compounds are currently in clinical
trials (48, 49). A second class of compounds that are showing
promise in clinical trials are linear peptide-like molecules that
introduce an electrophilic -ketoamide group at the scissile
bond with which the catalytic serine can react to form a cova-
lent bond that is reversible (Fig. 3b) (50, 51).
Themajor complication for the development of therapeutics
targeting activities encoded by RNA viruses is the development
of drug-resistant mutants. Given the high mutation rate and
large size of RNA virus populations, essentially every single
non-lethal amino acid substitution possible will be present at
the start of drug therapy. Mutants capable of replicating in the
presence of the drug will then be rapidly selected. As antici-
pated, this scenario has played out for inhibitors of NS3 prote-
ase activity (52). Numerous positions of NS3 protease have
been shown to contribute to resistance in cell culture and in the
clinic. Many of the positions confer resistance to both macro-
cyclic and linear inhibitors. Amino acid residues of NS3 prote-
ase linked to drug resistance are shown in Fig. 3c. Many of these
FIGURE 2. a, NS3 protease-dependent cleavage sites: P6 –P4 residues of cleavage sites present in the HCV
polyprotein and cellular proteins required for activation of the innate immune response. b, NS3 protease
catalytic/chemical mechanism. See text for details.
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residues are actually quite far (7–8 Å) from the substrate-bind-
ing pocket (Fig. 3c).
Studies of HIV PR have provided substantial insight into
mechanisms of resistance and strategies to increase the barrier
to resistance (53, 54). Schiffer and co-workers have put forward
a very thought-provoking hypothesis for the apparent low bar-
rier to resistance observed for HIV PR inhibitors. They refer to
this hypothesis as the “substrate envelope hypothesis.” The fun-
damental tenet is that the inhibitor envelope (van der Waals
surface of the inhibitor) exceeds the substrate envelope. There-
fore, residues of HIV PR that confer tight binding of the inhib-
itor need not contribute to substrate binding. Amino acid sub-
stitutions at positions that are not essential for substrate
binding would lead to drug-resistant proteases and viruses that
are not debilitated for function. Additional second-site substitu-
tions could then restore any fitness loss associated with the initial
substitution.Apredictionof thishypothesis is thatby constraining
the inhibitor envelope to that of the substrate, the barrier to resis-
tance should be increased because loss of interaction with the
inhibitor should now correspond, minimally, to interference with
substrate binding. Initial studies testing the substrate envelope
hypothesis have supported the hypothesis (55).
Nalam and Schiffer (56) and Romano and Schiffer (57) have
further shown that the low barrier to resistance observed for
HCV NS3 inhibitors likely relates to the fact that the inhibitor
envelope exceeds the substrate envelope.4 The substrate enve-
lope for an NS3/NS4A junction peptide is shown in Fig. 3c.
Again,many amino acid residues involved in drug resistance do
not interact directly with the substrate. When the positions of
inhibitors are evaluated relative to this substrate envelope, the
inhibitor envelope is not coincidentwith the substrate envelope
(Fig. 3d). It is also evident from this figure how sites remote
from the substrate-binding site could lead to inhibitor resist-
ance without affecting substrate binding and/or cleavage and
therefore viral fitness. Application of the substrate envelope
hypothesis to the design of HCVNS3 protease inhibitors could
yield inhibitors with a high barrier to resistance.
NS3 Protease andTools to StudyHCV—In addition to being a
target for antiviral therapy, NS3 protease activity is being
exploited for the development of new assays to study viral infec-
tion in primary cell cultures (58), to perform live cell imaging
and analysis of individual infected cells (59), and to identify
inhibitors (60, 61). These new capabilities link localization,
activity, or function of a reporter to processing byNS3 protease
activity introduced into cells by infection.
NS3 Helicase
Nucleic Acid Binding and Oligomerization in Vitro—Heli-
cases are classified into superfamiles (SFs) based on sequence
homology, with SF1 and SF2 being the largest (62). NS3 is a
member of SF2. A thorough review on NS3 helicase (63) and
several excellent reviews on helicasemechanisms (64–67) have
recently been published. NS3 binds to DNA and RNA with an
equilibrium dissociation constant in the low nM range, a bind-
ing site size of 7–8 nt, and little or no reported cooperativity
(68). Binding to RNA and DNA, as well as unwinding of both
substrates, is enhanced at pH 6.5 (69). It is not known
whether the pH dependence observed in vitro has biological
significance, but it may indicate a unique environment within
the membranous web where HCV replication occurs (11).
NS3 interacts with itself in vitro to form large aggregated
structures, but it is not known whether oligomerization is bio-
logically significant (70). The active form of NS3 has been stud-
ied by several laboratories with different conclusions regarding
the active species including monomer (71–73), dimer (74, 75),
and oligomer (70). Evidence indicates thatmonomeric NS3 can
rapidly unwind RNA, albeit with relatively low processivity (73,
76). The NS3 helicase domain (NS3h), unlike NS3 or NS3/
NS4A, does not readily interact with itself (70). However, NS3h
unwinding activity is increased when multiple molecules bind
to the same DNA substrate molecule. This phenomenon is
referred to as functional cooperativity, which results from all of
the bound enzymes translocating in the same direction on the
tracking strand of the substrate (77).
Kinetic and PhysicalMechanism for DNA and RNAUnwind-
ing—Unwinding of duplexes of varying length has led to several
descriptors of the kinetic and physical constants associated
with helicases (78). Unwinding experiments reveal a distinct lag
phase, which can be interpreted to determine the kinetic step
size for unwinding, which is the number of base pairs unwound
prior to a rate-limiting kinetic step. The physical step size refers
to the number of base pairs unwound in a single physical step. A
helicase can unwind 1 bp at a time (physical step of one) but
then proceed through a slow conformational change that4 C. A. Schiffer, personal communication.
FIGURE 3. a, amino acid residues of the substrate-binding pocket of NS3 pro-
tease. Residues capable of interacting with a peptide substrate are shown.
Catalytic residues are underlined. b, examples of NS3 protease inhibitors. The
macrocyclic TMC435 (Protein Data Bank code 3KEE) (99) and linear boceprevir
(code 2OC8) (51) and telaprevir analog (code 2P59) (100) are shown. c, NS3
substrate envelope. The van der Waals surface of the NS3/NS4A junction pep-
tide (gray) is shown relative to amino acids implicated in drug resistance (yel-
low). d, inhibitors extend beyond the substrate envelope (same as in c but
showing the positions of the inhibitors). Inhibitor locations are based on crys-
tal structures (51, 99, 100).
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occurs every 3 bp, resulting in a kinetic step size of 3 bp. NS3
exhibits a surprisingly large kinetic step size of 18 bp (79). Tack-
ett et al. (80) were able to fit DNA unwinding of a 30-bp sub-
strate to only two kinetic steps, implying a kinetic step size of at
least 15 bp. Levin et al. (77) reported a 9-bp kinetic step size for
NS3h. Dumont et al. (81) used high resolution optical tweezers
to measure RNA unwinding and reported that NS3 melts RNA
with an 11-bp kinetic step size.
An explanation for the large kinetic step sizes must involve a
periodic slow step in the kinetic mechanism. Slow dissociation
of the displaced strand was proposed to account for the large
kinetic step size (73). NS3 binds more tightly to DNA or RNA
comparedwithNS3h, so the protease domainmay interactwith
the nucleic acid, perhaps by binding to the displaced strand.
Identification of residues that interact with the displaced strand
is now needed to test this hypothesis.
NS3 contains a number of highly conserved helicase motifs
that line the cleft between domains 1 and 2 or face into the
binding site for single-stranded DNA (ssDNA) (Fig. 1c). Struc-
ture-function studies have led to a description of the role for
many of these motifs in ATP binding and hydrolysis or interac-
tion with nucleic acid (82, 83). The first structure of NS3h
bound to ssDNA led to a proposed inchworm model for
unwinding activity (84). Translocation of the helicase was sug-
gested to result from movement of domains 1 and 2 relative to
one another as a function of ATP binding and hydrolysis. The
inchwormmechanism for other helicases has received support
from structural (84–87) and biochemical (88) studies.
The proposed inchworm model for NS3h was further sup-
ported by recent structures of NS3h co-crystallized with ATP
analogs and ssDNA (Fig. 4, a and b) (89). The ATP analog
ADPBeF3mimics the ground state of ATP, whereas ADPAlF4
mimics the transition state for ATP hydrolysis. Two amino
acids of particular importance to the mechanism are Trp-501
and Val-432, which form “bookends” for the tracking strand of
ssDNA bound in the active site of the enzyme. Trp-501 stacks
with a base at the 3-end of the ssDNA, whereas Val-432 inserts
between bases on the 5-end of the ssDNA (Fig. 4c). Five nt of
the tracking strand are bound to the enzyme between the book-
end residues in the absence of ATP.When bound to ADPBeF3,
NS3h undergoes a conformational change, with domains 1 and
3 rotating in the 5-direction and closing with domain 2 (Fig.
4b). Domain movement results in 1 nt sliding outside the bind-
ing site at the position of Trp-501, leaving only 4 nt between the
bookend residues. The structure of NS3h in the presence of the
ATP transition state analog ADPAlF4 illustrates intradomain
movements that accompany the domain rotations. The net
effect of these molecular motions is to rearrange interactions
with nucleotides that ensure unidirectional movement along
the binding track (Fig. 4c). ATP hydrolysis is proposed to
release the closed conformation, allowing domain 2 to move in
the 5-direction by 1 nt. The net result is movement of 1 nt per
ATP hydrolyzed (Fig. 4d). Key to this mechanism is that Val-
432 and additional contacts from domain 2 hold the 5-end of
the ssDNA in place during movement of domains 1 and 3,
whereas stacking of Trp-501 and additional ssDNA contacts
hold the 3-end of the ssDNA while domain 2 moves forward.
Changing Trp-501 or Val-432 to alanine greatly reduces DNA
unwinding activity, consistent with the inchworm mechanism
(83). Movement of the DNA through the active site has also
been proposed to be driven in part by electrostatic repulsion
between theDNAand a glutamate residue (Glu-493) thatmain-
tains an unusually high pKa value (90).
An alternative mechanism to the inchworm model is the
Brownian ratchet mechanism, in which NS3 diffuses along the
DNA as a result of ATP-dependent cycling between tight and
weak binding states (91). In the weak binding state, ATP binding
causes the enzyme to have reduced affinity for ssDNA. Brownian
motion allows the enzyme to slide forward or backward in the
weakly bound state.Movement in the 3-to-5-direction is favored
owing to the ratchet effect presumably due to Trp-501, which
reduces the probability of the enzyme sliding backward.
Another region ofNS3 that is critical for unwinding is a-hair-
pin that extends fromdomain 2 (Fig. 1c). This has been referred to
as thePhe loopdue to twoconservedphenylalanine residues in the
turn of the hairpin (92). The role of the hairpin was inferred from
thestructureof thearchaealSF2helicaseHel308,whichwassolved
in the presence of a single-stranded/double-stranded DNA junc-
tion (93). Thepin appears to serve as awedge that splits theduplex
DNA. A recent report for the SF1 helicase RecD2 showed that
removal of the corresponding pin domain abolished double-
stranded DNA unwinding without affecting DNA-stimulated
ATPase activity (94). Hence, a likely role for the -hairpin (Phe
loop) is to separate the incoming duplex.
Data from single-molecule fluorescence resonance energy
transfer experiments support a 3-bp step size in a “spring-
loaded” mechanism for NS3 (72). The 3-bp physical step size
was determined to include smaller 1-bp steps that are likely
associated with one ATP hydrolysis event. These data led to a
FIGURE 4. a, structure of NS3h in complex with ssDNA. Coordinates are from
Protein Data Bank code 3KQH. Domains 1, 2, and 3 are colored blue, green, and
yellow, respectively. b, movement of domain 2 during ATP hydrolysis. Coor-
dinates are from code 3KQL, the NS3h-ssDNA-ADPAlF4
 complex. c, amino
acid residues required for translocation (ribbon diagram of the structure
shown in b highlighting the position of Val-432 and Trp-501 relative to nucleic
acid). d, model for translocation and unwinding by NS3 invoking a 1-bp phys-
ical step size (84, 89). Domain colors match those in A, and the base stacked
with Trp-501 is indicated in red. ATP binding leads to movement of domains 1
and 3 in the 3-to-5-direction along the tracking strand, leading to 1 nt
emerging from the ssDNA-binding site. ATP hydrolysis leads to movement of
domain 2, resulting in melting of 1 bp and returning the enzyme to its initial
state. This schematic does not depict all of the possible enzyme states that must
occur along the reaction pathway. For example, more subtle conformational
changes, transition states for ATP hydrolysis, and intermediate states with ADP
and Pi bound must occur but are not shown for clarity. A similar model invoking a
1-nt substep and a 3-bp unwinding step has been proposed (72).
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proposed variation of the inchworm mechanism whereby
domains 1 and 2move along theDNAstrandby 1nt for eachATP
hydrolyzed, whereas domain 3 remains anchored to the DNA
through its tight interaction via Trp-501. Domain 3 was proposed
to spring ahead after building up strain in the enzyme, resulting in
the unwinding of 3 bp andproviding an explanation for the single-
molecule fluorescence resonance energy transfer data.
Progress has been made in determining the specific step in the
kinetic mechanism that limits duplex unwinding. The rate of
phosphate release after ATP hydrolysis occurred at the same rate
as the rate of unwinding of a 9-bp RNA duplex, suggesting that
phosphate release may contribute to the rate-limiting step (95).
Recently, theATPasekinetic cycleof theDEADboxproteinDbpA
showed that one ATP hydrolysis event leads to unwinding of an
8-bp duplex (96). For this enzyme, the release of RNAoccurs after
ATP hydrolysis but prior to phosphate release.
Although RNA is the biological substrate for NS3 helicase,
the enzyme exhibits robust DNA binding and unwinding activ-
ities. NS3 has been found in the nuclei of liver cells in patients
infected withHCV (97). To date, no direct connection has been
made between the DNA unwinding activity of NS3 and the
pathobiology of HCV.
Inhibitors of NS3 Helicase Activity—No inhibitors of NS3
helicase activity have entered clinical trials. The helicase has
not been found to recognize anRNAsequence or structurewith
high specificity, which is in contrast to the active site of theNS3
protease. Therefore, it may be difficult to find molecules that
bind to the active site of NS3 and that do not exhibit cross-
reactivity with the myriad other cellular helicases whose active
sites are similar to that ofNS3.High throughput helicase assays,
such as those with hairpin-forming molecular beacons, may
enable discovery of specific inhibitors (98). Structure-based
approaches might also yield success based on new structures
that reveal different conformations of the protein (89). Finally,
disruption of protein-protein interactions between NS3 and
other HCV structural or non-structural proteins may impair
HCV replication.
Acknowledgment—We thank Jamie Arnold for assistance in prepara-
tion of the figures.
REFERENCES
1. Knipe, D. M., Howley, P. M., Griffin, D. E., Lamb, R. A., Martin, M. A,
Roizman, B., and Straus, S. E. (2007) Fields Virology, 5 Ed., Lippincott
Williams &Wilkins, Philadelphia
2. Lohmann, V., Körner, F., Koch, J., Herian, U., Theilmann, L., and Barten-
schlager, R. (1999) Science 285, 110–113
3. Behrens, S. E., Tomei, L., andDe Francesco, R. (1996) EMBO J. 15, 12–22
4. Tanji, Y., Kaneko, T., Satoh, S., and Shimotohno, K. (1995) J. Virol. 69,
3980–3986
5. Huang, L., Hwang, J., Sharma, S. D., Hargittai, M. R., Chen, Y., Arnold,
J. J., Raney, K. D., and Cameron, C. E. (2005) J. Biol. Chem. 280,
36417–36428
6. Shimakami, T., Hijikata, M., Luo, H., Ma, Y. Y., Kaneko, S., Shimotohno,
K., and Murakami, S. (2004) J. Virol. 78, 2738–2748
7. Macdonald, A., and Harris, M. (2004) J. Gen. Virol. 85, 2485–2502
8. Waller, H., Chatterji, U., Gallay, P., Parkinson, T., and Targett-Adams, P.
(2010) J. Virol. Methods, in press
9. Tellinghuisen, T. L., Foss, K. L., and Treadaway, J. (2008) PLoS Pathog. 4,
e1000032
10. Appel, N., Zayas, M., Miller, S., Krijnse-Locker, J., Schaller, T., Friebe, P.,
Kallis, S., Engel, U., and Bartenschlager, R. (2008) PLoS Pathog. 4,
e1000035
11. Egger, D., Wölk, B., Gosert, R., Bianchi, L., Blum, H. E., Moradpour, D.,
and Bienz, K. (2002) J. Virol. 76, 5974–5984
12. Konan, K. V., Giddings, T. H., Jr., Ikeda, M., Li, K., Lemon, S. M., and
Kirkegaard, K. (2003) J. Virol. 77, 7843–7855
13. Failla, C., Tomei, L., and De Francesco, R. (1994) J. Virol. 68, 3753–3760
14. Grakoui, A., McCourt, D.W.,Wychowski, C., Feinstone, S. M., and Rice,
C. M. (1993) J. Virol. 67, 2832–2843
15. Tomei, L., Failla, C., Santolini, E., De Francesco, R., and La Monica, N.
(1993) J. Virol. 67, 4017–4026
16. Grakoui, A., McCourt, D.W.,Wychowski, C., Feinstone, S. M., and Rice,
C. M. (1993) Proc. Natl. Acad. Sci. U.S.A. 90, 10583–10587
17. Li, K., Foy, E., Ferreon, J. C., Nakamura,M., Ferreon, A. C., Ikeda,M., Ray,
S. C., Gale, M., Jr., and Lemon, S. M. (2005) Proc. Natl. Acad. Sci. U.S.A.
102, 2992–2997
18. Ferreon, J. C., Ferreon,A.C., Li, K., and Lemon, S.M. (2005) J. Biol. Chem.
280, 20483–20492
19. Cheng, G., Zhong, J., andChisari, F. V. (2006)Proc. Natl. Acad. Sci. U.S.A.
103, 8499–8504
20. Suzich, J. A., Tamura, J. K., Palmer-Hill, F., Warrener, P., Grakoui, A.,
Rice, C. M., Feinstone, S. M., and Collett, M. S. (1993) J. Virol. 67,
6152–6158
21. Rajkowitsch, L., Chen, D., Stampfl, S., Semrad, K., Waldsich, C., Mayer,
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